SLC5A2 and diabetes mellitus: The results of the EMPEROR-Preserved and DELIVER trials support the implementation of SGLT2 inhibitors as a suggested pharmacological approach for patients with HFpEF, especially for those who present with additional risk factors such as diabetes and hypertension [17,51].